Fed. Circ. Pauses 'Orange Book' Delisting For Jazz Drug
Jazz Pharmaceuticals will be allowed to list its patent for a narcolepsy drug in health regulators' roster of approved drugs, at least for the near future, after the Federal Circuit granted the company's...To view the full article, register now.
Already a subscriber? Click here to view full article